An Intrinsic Calculation For CSL Limited (ASX:CSL) Suggests It's 20% Undervalued
May 01
Australian (ASX) Biotech Industry Analysis
UpdatedMay 02, 2024
DataAggregated Company Financials
Companies33
- 7D-1.2%
- 3M-5.7%
- 1Y-7.4%
- YTDn/a
Last week, the Biotech industry hasn't moved much but Telix Pharmaceuticals is up 5.2% in that time. As for the longer term, the industry has declined 7.9% in the last year. Earnings are forecast to grow by 16% annually.
Industry Valuation and Performance
Has the Australian Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Thu, 02 May 2024 | AU$142.3b | AU$22.6b | AU$3.3b | 30x | 43x | 6.3x |
| Sat, 30 Mar 2024 | AU$147.5b | AU$22.5b | AU$3.3b | 30.3x | 44.7x | 6.5x |
| Mon, 26 Feb 2024 | AU$144.9b | AU$22.4b | AU$3.3b | 36.6x | 43.7x | 6.5x |
| Wed, 24 Jan 2024 | AU$149.0b | AU$20.9b | AU$2.8b | 34x | 53.8x | 7.1x |
| Fri, 22 Dec 2023 | AU$143.6b | AU$20.3b | AU$2.7b | 34.2x | 53.5x | 7.1x |
| Sun, 19 Nov 2023 | AU$131.6b | AU$21.1b | AU$2.8b | 32x | 46.9x | 6.3x |
| Tue, 17 Oct 2023 | AU$123.8b | AU$21.8b | AU$2.9b | 29.8x | 43.2x | 5.7x |
| Thu, 14 Sep 2023 | AU$137.7b | AU$21.4b | AU$2.8b | 32.4x | 49.1x | 6.4x |
| Sat, 12 Aug 2023 | AU$136.3b | AU$18.4b | AU$2.4b | 38.4x | 57.1x | 7.4x |
| Mon, 10 Jul 2023 | AU$137.4b | AU$18.0b | AU$2.3b | 36.7x | 59.2x | 7.6x |
| Wed, 07 Jun 2023 | AU$157.2b | AU$18.1b | AU$2.3b | 41.3x | 67.3x | 8.7x |
| Fri, 05 May 2023 | AU$153.9b | AU$18.0b | AU$2.3b | 41.2x | 66.3x | 8.6x |
| Sun, 02 Apr 2023 | AU$146.9b | AU$18.0b | AU$2.3b | 40x | 63.4x | 8.2x |
| Tue, 28 Feb 2023 | AU$151.5b | AU$17.7b | AU$2.3b | 41.5x | 65.8x | 8.5x |
| Thu, 26 Jan 2023 | AU$152.1b | AU$15.3b | AU$2.4b | 55.1x | 63x | 10x |
| Sat, 24 Dec 2022 | AU$147.5b | AU$16.1b | AU$2.6b | 46.1x | 57.5x | 9.2x |
| Mon, 21 Nov 2022 | AU$150.5b | AU$16.1b | AU$2.6b | 43.5x | 58.9x | 9.4x |
| Wed, 19 Oct 2022 | AU$141.0b | AU$17.1b | AU$2.7b | 40.7x | 51.3x | 8.3x |
| Fri, 16 Sep 2022 | AU$146.7b | AU$15.9b | AU$2.5b | 46x | 57.7x | 9.2x |
| Sun, 14 Aug 2022 | AU$149.6b | AU$15.2b | AU$2.7b | 41.7x | 54.9x | 9.9x |
| Tue, 12 Jul 2022 | AU$145.8b | AU$15.7b | AU$2.8b | 37.5x | 51.4x | 9.3x |
| Thu, 09 Jun 2022 | AU$135.2b | AU$15.0b | AU$2.7b | 35.2x | 50.1x | 9x |
| Sat, 07 May 2022 | AU$135.6b | AU$15.1b | AU$2.8b | 35.7x | 49.1x | 9x |
| Mon, 04 Apr 2022 | AU$135.7b | AU$14.4b | AU$2.6b | 39.1x | 52.2x | 9.5x |
| Wed, 02 Mar 2022 | AU$134.5b | AU$14.9b | AU$2.6b | 41.3x | 52.1x | 9x |
| Fri, 28 Jan 2022 | AU$128.8b | AU$14.6b | AU$2.8b | 36x | 46.3x | 8.8x |
| Sun, 26 Dec 2021 | AU$152.1b | AU$14.5b | AU$2.8b | 42.6x | 55.1x | 10.5x |
| Tue, 23 Nov 2021 | AU$156.9b | AU$14.4b | AU$2.7b | 44x | 57.4x | 10.9x |
| Thu, 21 Oct 2021 | AU$147.9b | AU$14.0b | AU$2.6b | 42.7x | 56.1x | 10.6x |
| Sat, 18 Sep 2021 | AU$153.8b | AU$14.4b | AU$2.7b | 43.2x | 56.7x | 10.7x |
| Mon, 16 Aug 2021 | AU$146.3b | AU$14.0b | AU$2.6b | 42.7x | 55.7x | 10.5x |
| Mon, 31 May 2021 | AU$142.6b | AU$13.5b | AU$2.8b | 39.9x | 50.3x | 10.5x |
Price to Earnings Ratio
46.8x
Current Industry PE
- Investors are pessimistic on the Australian Biotechnology industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The industry is trading at a PE ratio of 43.6x which is lower than its 3-year average PE of 54.2x.
- The 3-year average PS ratio of 8.6x is higher than the industry's current PS ratio of 6.4x.
Past Earnings Growth
- The earnings for companies in the Biotechnology industry have grown 5.0% per year over the last three years.
- Revenues for these companies have grown 18% per year.
- This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.
Industry Comparison
How does Australian Biotech compare with similar industries?
| AU Market | -1.54% | |
| Healthcare | -1.12% | |
| Biotech | -1.25% | |
| Biotech | -1.25% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| MSB Mesoblast | AU$1.10 | 20.2% +AU$211.1m | 14.0% | PS109.3x | |
| PYC PYC Therapeutics | AU$0.097 | 4.3% +AU$36.7m | 61.7% | PS21.3x | |
| ACW Actinogen Medical | AU$0.038 | 31.0% +AU$20.9m | -40.6% | PS18.4x | |
| IMU Imugene | AU$0.084 | 1.2% +AU$7.3m | -32.8% | PS40.9x | |
| CUV Clinuvel Pharmaceuticals | AU$15.06 | 0.5% +AU$3.4m | -23.6% | PE25x |
